Clinical trial registry record

Safety & Tolerability of the IRay System in Subjects With Exudative Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)

A registered PHASE1 study indexed because it matched monitored longevity research terms. Registry status: Unknown. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Unknown.
Evidence
Registered phase 1 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated January 19, 2012.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT01217762
Last registry update
January 19, 2012
Status
Unknown
Phase
Phase 1
Sponsor
Oraya Therapeutics, Inc.
Enrollment
62
Countries
Mexico
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE1 study indexed because it matched monitored longevity research terms. Registry status: Unknown. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 1
Study design
NON RANDOMIZED · PARALLEL · TREATMENT · NONE
Evidence population
Human clinical study registration
Participants
62
Population
ALL · 50 Years
Duration
2008-07-01 to 2014-10-01
Intervention
IRay
Comparator
Not reported
Outcomes measured
Incidence of ocular radiation-related adverse events — Month 12; Incidence of ocular adverse events — Through month 60; Percentage of subjects who lose at least 15 Early Treatment Diabetic Retinopathy Study (ETDRS) letters in best correcte…; Percentage of subjects gaining ≥ 15 ETDRS letters — Month 12; Percentage of subjects gaining ≥ 0 ETDRS letters — Month 12; Mean change in ETDRS visual acuity — Month 12; Mean time to anti-VEGF retreatment following 2nd mandatory injection (excluding radiation-first subjects) — Month 12; Mean total number of ranibizumab injections — Through month 12 and 24; Change in choroidal neovascularization (CNV) size by fluorescein angiography (FA) — Month 12; Change in total lesion size by fluorescein angiography (FA) — Month 12; Change in central retinal lesion thickness by optical coherence tomography (OCT) — Month 12; Change in central subfield thickness by optical coherence tomography (OCT) — Month 12
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 1A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Vision ageing · 100%Title contains controlled topic terminology. Summary contains controlled topic terminology. Source terminology contains a controlled topic term. Title supplies ageing or longevity context.

Automated source check 100% · update recency 35%. These figures help sort records; they are not medical ratings.

vision aging
Read the original source →Export JSON